Oncolytic virus therapy for cancer

Goldufsky, Joe; Sivendran, Shanthi; Harcharik, Sara; Pan, Michael; Bernardo, Sebastian; Stern, R.H.; Friedlander, Philip; Ruby, Carl E.; Saenger, Yvonne M.; Kaufman, Howard L.

doi:10.2147/ov.s38901

Cited by 33 publications

(28 citation statements)

References 124 publications

(145 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Viruses exhibit cellular tropism which defines their ability to preferentially infect a specific tissue. A number of viruses have been shown to naturally extend their tropism to tumor cells [ 4 ]. Reovirus, parvovirus, Newcastle disease virus (NDV), Moloney leukemia virus (MLV) and mumps virus (MV) are among the viruses showing natural preference for tumor cells, while viruses such as vesicular stomatitis virus (VSV), measles virus (MV), vaccinia virus (VV), adenovirus (AdV), and herpes simplex virus (HSV) have been genetically modified or adapted to infect tumor cells [ 5 ].…”

Section: Introductionmentioning

confidence: 99%

“…Reovirus, parvovirus, Newcastle disease virus (NDV), Moloney leukemia virus (MLV) and mumps virus (MV) are among the viruses showing natural preference for tumor cells, while viruses such as vesicular stomatitis virus (VSV), measles virus (MV), vaccinia virus (VV), adenovirus (AdV), and herpes simplex virus (HSV) have been genetically modified or adapted to infect tumor cells [ 5 ]. Oncolytic viruses have recently become a promising tool for treating cancer by producing lysis of tumor cells or inducing an immune response to them [ 4 ]. Some desirable characteristics of viruses can be modified by redesigning their genome in order to improve viral tropism to neoplastic cells, enhance lytic capacity or induce antitumor immunity [ 5 ].…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Experimental Adaptation of Rotaviruses to Tumor Cell Lines

Guerrero

Silva

et al. 2016

PLoS ONE

View full text Add to dashboard Cite

A number of viruses show a naturally extended tropism for tumor cells whereas other viruses have been genetically modified or adapted to infect tumor cells. Oncolytic viruses have become a promising tool for treating some cancers by inducing cell lysis or immune response to tumor cells. In the present work, rotavirus strains TRF-41 (G5) (porcine), RRV (G3) (simian), UK (G6-P5) (bovine), Ym (G11-P9) (porcine), ECwt (murine), Wa (G1-P8), Wi61 (G9) and M69 (G8) (human), and five wild-type human rotavirus isolates were passaged multiple times in different human tumor cell lines and then combined in five different ways before additional multiple passages in tumor cell lines. Cell death caused by the tumor cell-adapted isolates was characterized using Hoechst, propidium iodide, 7-AAD, Annexin V, TUNEL, and anti-poly-(ADP ribose) polymerase (PARP) and -phospho-histone H2A.X antibodies. Multiple passages of the combined rotaviruses in tumor cell lines led to a successful infection of these cells, suggesting a gain-of-function by the acquisition of greater infectious capacity as compared with that of the parental rotaviruses. The electropherotype profiles suggest that unique tumor cell-adapted isolates were derived from reassortment of parental rotaviruses. Infection produced by such rotavirus isolates induced chromatin modifications compatible with apoptotic cell death.

show abstract

Section: Introductionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

Experimental Adaptation of Rotaviruses to Tumor Cell Lines

Guerrero

Silva

et al. 2016

PLoS ONE

View full text Add to dashboard Cite

show abstract

“…Although the safety of replication-selective adenoviruses was proven in numerous clinical trials, single agent treatment with oncolytic adenoviruses have only resulted in moderate efficacy 26,65 . However, treatment efficacy was increased when the mutants were combined with chemotherapy 26,66 .…”

Section: Combination Of Oncolytic Adenoviruses With Chemotherapymentioning

confidence: 99%

Designer Oncolytic Adenovirus: Coming of Age

Baker¹,

Aguirre-Hernández²,

Halldén³

et al. 2018

Preprint

View full text Add to dashboard Cite

The licensing of Talimogene Laherparepvec (T-Vec) represented a landmark moment for oncolytic virotherapy, since it provided unequivocal evidence for the long-touted potential of genetically modified replicating viruses as anti-cancer agents. Whilst T-Vec is promising as a locally delivered virotherapy, especially in combination with Immune-checkpoint inhibitors, the quest continues for a virus capable of specific tumour cell killing via systemic administration. One candidate is oncolytic Adenovirus; it’s double stranded DNA genome is easily manipulated and a wide range of strategies and technologies have been employed to empower the vector with improved pharmacokinetics and tumour targeting ability. As well characterised clinical and experimental agents we have detailed knowledge of Adenoviruses mechanisms of pathogenicity, supported by detailed virological studies and in vivo interactions. In this review we highlight the strides made in the engineering of bespoke adenoviral vectors to specifically infect, replicate within, and destroy tumour cells. We discuss how mutations in genes regulating adenoviral replication after cell entry can be used to restrict replication to the tumour, and summarise how detailed knowledge of viral capsid interactions enable rational modification to eliminate native tropisms, and simultaneously promote active uptake by cancerous tissues. We argue that these designer-viruses, exploiting the viruses natural mechanisms and regulated at every level of replication, represent the ideal platforms for local overexpression of therapeutic transgenes such as immunomodulatory agents. Where T-Vec has paved the way, Ad based vectors now follow. The era of designer oncolytic virotherapies looks decidedly as though it will soon become a reality.

show abstract

“…In 2005, the first genetically engineered oncolytic virus, H101 Adenovirus, was approved for treatment of SCCHN in China [49]. Advanced stage cancer patients showed a 79% response rate with both chemotherapy and the modified adenovirus, as compared to a 40% response rate with chemotherapy alone [50]. These results suggested the promising outcome of using gene therapy as an adjunct for the management of cancers.…”

Section: Applications In Dentistrymentioning

confidence: 99%

Gene Therapy: A Paradigm Shift in Dentistry

Siddique

Raza

Ahmed

et al. 2016

Genes

View full text Add to dashboard Cite

Gene therapy holds a promising future for bridging the gap between the disciplines of medicine and clinical dentistry. The dynamic treatment approaches of gene therapy have been advancing by leaps and bounds. They are transforming the conventional approaches into more precise and preventive ones that may limit the need of using drugs and surgery. The oral cavity is one of the most accessible areas for the clinical applications of gene therapy for various oral tissues. The idea of genetic engineering has become more exciting due to its advantages over other treatment modalities. For instance, the body is neither subjected to an invasive surgery nor deep wounds, nor is it susceptible to systemic effects of drugs. The aim of this article is to review the gene therapy applications in the field of dentistry. In addition, therapeutic benefits in terms of treatment of diseases, minimal invasion and maximum outcomes have been discussed.

show abstract

Oncolytic virus therapy for cancer

Cited by 33 publications

References 124 publications

Experimental Adaptation of Rotaviruses to Tumor Cell Lines

Experimental Adaptation of Rotaviruses to Tumor Cell Lines

Designer Oncolytic Adenovirus: Coming of Age

Gene Therapy: A Paradigm Shift in Dentistry

Contact Info

Product

Resources

About